6 insiders reported 7 Form 4 transactions for Inhibikase Therapeutics, Inc. (IKT) over the past 18 months (most recent 2026-02-24). Recent activity: Munshi Amit (Director) Sell 19,089 shares, Aurentz Vincent (Director) Sell 255,299 shares, Cabell Christopher (President & Head of R&D) Sell 338,282 shares, Sands Capital Alternatives, LLC (Insider) Buy 2.1M shares, SANDS FRANK M. (Insider) Buy 2.1M shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | Munshi Amit | Director | Sell | 19,089 | $0 |
| 2026-02-24 | Aurentz Vincent | Director | Sell | 255,299 | $0 |
| 2026-02-24 | Cabell Christopher | President & Head of R&D | Sell | 338,282 | $0 |
| 2025-11-24 | Sands Capital Alternatives, LLC | Insider | Buy | 2.1M | $3.0M |
| 2025-11-24 | SANDS FRANK M. | Insider | Buy | 2.1M | $3.0M |
| 2025-11-24 | Sands Capital Life Sciences Pulse Fund II, L.P. | Insider | Buy | 2.1M | $3.0M |
| 2025-08-28 | Munshi Amit | Director | Buy | 57,265 | $0 |
Source: SEC Form 4 filings · as of 2026-02-24